500 Kendall Street
About Sanofi Genzyme
Genzyme is committed to discovering and delivering transformative therapies for patients with rare and special unmet medical needs, providing hope where there was none before.
Genzyme has pioneered the development and delivery of transformative therapies for over 30 years. Founded in 1981 in Boston, Massachusetts, Genzyme evolved from a tiny start-up with just a handful of employees to one of the world's leading biotech companies. Acquired by Sanofi in 2011, Genzyme now benefits from the reach and resources of one of the world’s largest pharmaceutical companies, with a shared commitment to improving the lives of patients.
Genzyme has long been known for our expertise in the class of rare genetic diseases known as lysosomal storage disorders (LSDs). LSDs remain the heart of our company today, but we have also expanded – through both in-house development and strategic acquisitions and partnerships – to other disease areas such as thyroid cancer and multiple sclerosis.
Sanofi, a global and diversified healthcare leader, discovers, develops and distributes therapeutic solutions focused on patients’ needs. Sanofi has core strengths in the field of healthcare with seven growth platforms: diabetes solutions, human vaccines, innovative drugs, rare diseases, consumer healthcare, emerging markets, and animal health. Sanofi is listed in Paris (EURONEXT: SAN) and in New York (NYSE: SNY).
776 articles with Sanofi Genzyme
Sanofi and Regeneron made a deal with pharmacy benefits manager Express Scripts for their Praluent, making it the exclusive PCSK9 inhibitor on their national formulary, essentially locking Amgen’s Repatha out of that market segment.
Regeneron and its longtime development partner Sanofi are keeping their proverbial fingers crossed that their profitable collaboration will yield yet another approved treatment this year.
FDA to Conduct Priority Review of Cemiplimab as a Potential Treatment for Advanced Cutaneous Squamous Cell Carcinoma
The U.S. Food and Drug Administration (FDA) has accepted for priority review the Biologics License Application (BLA) for cemiplimab for the treatment of patients with metastatic cutaneous squamous cell carcinoma (CSCC) or patients with locally advanced CSCC who are not candidates for surgery.
Paris-based Sanofi reported mixed first-quarter revenues, with net sales down 8.7 percent to 7,898 million euros. But Sanofi Genzyme sales were up 16.2 percent, mostly the result of its new immunology franchise.
Applied BioMath, LLC Announces Collaboration with Sanofi Genzyme for Systems Pharmacology Modeling of Bispecific Antibody Therapeutics in Immunology
Applied BioMath announced a collaboration with Sanofi Genzyme for the analysis of systems pharmacology pharmacokinetic (PK)/target engagement (TE) models for multi-specific antibody combinations.
Sanofi announced that Elias Zerhouni, head of Global Research and Development, is retiring on June 30. The company has appointed John Reed to replace him as of July 1.
Relapsing MS Patients Who Switched to Aubagio® (teriflunomide) Reported Increased Treatment Satisfaction in Two Clinical Studies
Patients with relapsing multiple sclerosis who switched to Sanofi Genzyme’s Aubagio® (teriflunomide) from interferon therapy experienced improvements in treatment satisfaction, according to investigational data from two clinical studies.
Badrul Chowdhury, director of the U.S. Food and Drug Administration (FDA)’s Center for Drug Evaluation and Research (CDER)’s Division of Pulmonary, Allergy and Rheumatology Products, has left the agency to take a position as senior vice president of research development at AstraZeneca and MedImmune.
More Than 25 Data Presentations from Sanofi Genzyme’s Multiple Sclerosis Franchise to Be Featured at AAN
New investigational data on Sanofi Genzyme’s marketed treatments for relapsing multiple sclerosis (MS), Lemtrada® (alemtuzumab) and Aubagio® (teriflunomide), will be presented at the 70th annual meeting of the American Academy of Neurology (AAN).
Sanofi has agreed to sell its generics division, Zentiva, to Advent International. The deal is expected to wrap by the end of this year.
Shares of Ironwood Pharma have settled a bit after the company announced Monday that activist investor Alex Denner of Sarissa Capital was vying for a seat on the company board of directors.
4/10/2018Pfizer joined the TriNetX global health research network, which will allow it to access clinical data from the network’s healthcare organizations.
More than a dozen advertisers, including Johnson & Johnson and Bayer, have boycotted the Fox News show, “The Ingraham Angle,” after its host, Laura Ingraham, 54, bullied high school student David Hogg.
Realm Therapeutics announced today that its PR013, failed to show efficacy in its Phase II trial for allergic conjunctivitis.
Alnylam Retains Global Rights to Lumasiran, an Investigational RNAi Therapeutic for the Treatment of Primary Hyperoxaluria Type 1 (PH1)
Company plans to accelerate development with Phase 3 start in late 2018.
Today, on this 11th World Rare Disease Day, life science companies, organization and activists have come together to raise awareness about these diseases and the needs of therapies for patients.
Cambridge, Massachusetts-based Generation Bio closed on a $100 million Series B financing today.
The passing of tax reform led most analysts to predict that 2018 will be a strong year for mergers and acquisitions.
Koss said affected employees will receive severance benefits and career guidance.
The effort was announced last week by the Henri A. Termeer Tribute Committee.